Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report

BRAF fusions are rare driver oncogenes in non-small cell lung cancer (NSCLC). Similar with BRAF V600E mutation, it could also activate the MAPK signaling pathway. There are a few case reports which had indicated the potential response to BRAF inhibitors and its important role as de novo driver mutat...

Descripción completa

Detalles Bibliográficos
Autores principales: Chou, Yun-Tse, Lin, Chien-Chung, Lee, Chung-Ta, Pavlick, Dean C., Su, Po-Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972191/
https://www.ncbi.nlm.nih.gov/pubmed/35372088
http://dx.doi.org/10.3389/fonc.2022.838798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972191/
https://www.ncbi.nlm.nih.gov/pubmed/35372088
http://dx.doi.org/10.3389/fonc.2022.838798

Ejemplares similares